The ES90 is notable for being the first electric saloon from the Swedish automaker - marking a shift away from its traditional SUV offerings. The car can accelerate from 0-62mph in as little as 4. ...

Saloon Stock Cars – rough, hard-hitting action-packed racing The hard-hitting, action-packed Saloon Stock Cars typically only make occasional visits to race in Cornwall, but for the 2025 season, they ...

Kia promised lots with the EV4 Concept and it has delivered Both a saloon and hatchback will be ... mash-up EV6 and the forthcoming EV2 city car to deliver an electrified option to suit most ...

Here we are then, Volvo’s return to low-flying motor cars. After the TG Award-winning EX90 SUV comes this, the brand new ES90. It’s a large, luxury electric... saloon? Fastback? Hatchback?

Last year, NASCAR finally unveiled a prototype meant to illustrate what an electric stock car racing series could look like. That car was shaped like a crossover, but one notably not meant to ...

Even those who don't follow car news in particular have been reading all about Tesla's recent stock troubles. At last check, Tesla's stock price was on a five-day freefall, and down by more than a ...

Volvo may have mastered the SUV but it isn’t about to lose its grip on the ailing saloon car market as electric vehicles take off, as evidenced by the sleek, long-range and luxurious ES90. The Volvo ...

One stock to keep an eye on is Cars.com (CARS). CARS is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. Another notable valuation metric for CARS is its P/B ratio of 2.25.

We have 21 new BMW 8 Series cars available from offical BMW dealers. Browse now, and find the perfect new BMW 8 Series near you. In stock cars BMW 2 Series In stock cars BMW 2 Series Active Tourer ...

JPMorgan Chase & Co. currently has a neutral rating on the stock. Several other equities analysts also recently weighed in on CARS. UBS Group raised their price target on Cars.com from $17.00 to $ ...

I think Allogene presents a compelling opportunity to re-rate its stock, but failure would reinforce doubts about allogeneic CAR-T viability. The next two years will be decisive, and the upside is ...